Alzamend Neuro (ALZN) Competitors $0.96 -0.06 (-6.12%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.94 -0.01 (-1.32%) As of 02/21/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ALZN vs. ALLK, LVTX, PLUR, ENLV, DRRX, CTXR, COCP, CARA, TNXP, and SXTPShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Allakos (ALLK), LAVA Therapeutics (LVTX), Pluri (PLUR), Enlivex Therapeutics (ENLV), DURECT (DRRX), Citius Pharmaceuticals (CTXR), Cocrystal Pharma (COCP), Cara Therapeutics (CARA), Tonix Pharmaceuticals (TNXP), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Allakos LAVA Therapeutics Pluri Enlivex Therapeutics DURECT Citius Pharmaceuticals Cocrystal Pharma Cara Therapeutics Tonix Pharmaceuticals 60 Degrees Pharmaceuticals Alzamend Neuro (NASDAQ:ALZN) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Is ALZN or ALLK more profitable? Alzamend Neuro's return on equity of 0.00% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A N/A -289.14% Allakos N/A -140.87%-86.22% Which has higher earnings and valuation, ALZN or ALLK? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/AAllakosN/AN/A-$185.70M-$2.03-0.14 Do insiders & institutionals believe in ALZN or ALLK? 49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 10.6% of Alzamend Neuro shares are held by company insiders. Comparatively, 16.1% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, ALZN or ALLK? Alzamend Neuro has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Do analysts rate ALZN or ALLK? Alzamend Neuro currently has a consensus price target of $32.00, indicating a potential upside of 3,241.69%. Allakos has a consensus price target of $2.00, indicating a potential upside of 599.30%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alzamend Neuro is more favorable than Allakos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media refer more to ALZN or ALLK? In the previous week, Alzamend Neuro had 2 more articles in the media than Allakos. MarketBeat recorded 2 mentions for Alzamend Neuro and 0 mentions for Allakos. Alzamend Neuro's average media sentiment score of 0.87 beat Allakos' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the media. Company Overall Sentiment Alzamend Neuro Positive Allakos Neutral Does the MarketBeat Community believe in ALZN or ALLK? Allakos received 177 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformAlzamend NeuroOutperform Votes6100.00% Underperform VotesNo VotesAllakosOutperform Votes18358.84% Underperform Votes12841.16% SummaryAlzamend Neuro beats Allakos on 7 of the 12 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.54M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book-0.276.717.644.62Net Income-$9.95M$138.33M$3.18B$245.85M7 Day Performance-12.15%-2.61%-1.99%-2.68%1 Month Performance-18.85%-2.32%-0.42%-2.19%1 Year Performance-89.29%-5.31%16.51%12.84% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro2.6121 of 5 stars$0.96-6.1%$32.00+3,241.7%-88.9%$5.54MN/A0.004Negative NewsGap UpALLKAllakos4.225 of 5 stars$0.27+0.3%$2.00+632.3%-77.8%$24.34MN/A-0.13190LVTXLAVA Therapeutics2.9368 of 5 stars$0.91-4.6%$3.33+265.6%-50.9%$23.97M$6.77M-0.8960Gap UpPLURPluri0.2111 of 5 stars$4.31-3.3%N/A-30.3%$23.94M$330,000.00-0.71150ENLVEnlivex Therapeutics3.0716 of 5 stars$1.09-0.9%$9.50+771.6%-68.9%$23.34MN/A-1.1170DRRXDURECT3.3392 of 5 stars$0.75-1.3%$5.00+566.8%-10.9%$23.28M$8.55M-1.2380News CoverageCTXRCitius Pharmaceuticals2.8836 of 5 stars$2.70+1.1%$54.50+1,918.5%-90.6%$23.19MN/A-0.4520Earnings ReportAnalyst ForecastNews CoverageGap UpCOCPCocrystal Pharma2.6063 of 5 stars$2.28+24.6%$7.00+207.0%+32.7%$23.19MN/A-1.2310High Trading VolumeCARACara Therapeutics3.7606 of 5 stars$5.04+0.8%$27.84+452.4%-38.8%$23.03M$20.97M-0.2480News CoverageTNXPTonix Pharmaceuticals3.2463 of 5 stars$11.94-3.6%$5,350.00+44,707.4%-99.2%$22.33M$7.77M0.0050Gap UpSXTP60 Degrees Pharmaceuticals1.0377 of 5 stars$0.61+9.3%N/A+45.2%$22.13M$250,000.00-0.063Analyst ForecastNews Coverage Related Companies and Tools Related Companies Allakos Competitors LAVA Therapeutics Competitors Pluri Competitors Enlivex Therapeutics Competitors DURECT Competitors Citius Pharmaceuticals Competitors Cocrystal Pharma Competitors Cara Therapeutics Competitors Tonix Pharmaceuticals Competitors 60 Degrees Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALZN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
